bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events Read more about bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update Read more about bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
2021 Wedbush PacGrow Healthcare Conference Read more about 2021 Wedbush PacGrow Healthcare Conference
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events Read more about bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies Read more about Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
bluebird bio Second Quarter 2021 Earnings Conference Call Read more about bluebird bio Second Quarter 2021 Earnings Conference Call
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor Read more about bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU Read more about bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual Read more about betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual